Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study

Jiemei Gu,Hao Zhang,Qingyun Xue,Li Wang,Zhifeng Cheng,Yawei Zhang,Qifu Li,Lingqing Yuan,Yukun Li,Jin Dong,Yanan Huo, Xin Tang,Ling Hu,Xinjia Wang,Fei Hua,Lin Shen, Jinluo Cheng, Huimin Zhou,Youjia Xu,Tao Yang,Chuansuo Wang,Jin Xu,Jie Shen,Ying Zhang,Xiaomei Zhang,Dun Hong,Xiaoling Guan,Xinhua Xiao,Guang Wang,Yonghua Liu,Liujun Fu,Jianting Chen, Xigao Cheng,Yue Ding,Lijun Liu,Qi Yao,Xinchao Zhang,Lixin Li, Panjun Zhang,Chunying Deng, Chengyan Jiang,Li You,Kai Wang,Shimin Zhang,Jianzhong Xiao,Wei Liu, Xiaohong Du,Xianwen Shang,Tianrong Pan,Chen Lei, Shuren Guo,Zhenlin Zhang

Journal of Orthopaedic Translation（2023）

引用 2|浏览18

暂无评分

摘要

In this multi-center, randomized, double-blind, placebo-controlled phase 3 study, LY06006 showed substantially efficacy to increase BMD and well tolerance without unexpected adverse reactions, which is comparable to the reference drug Prolia ®. The presented results are encouraging and can offer some valuable evidence for the clinical practice.

查看译文

关键词

Biosimilar,Denosumab,Osteoporosis,Bone mineral density

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要